Commercialization Reports. LICENSEE, within thirty (30) days of the end of each Contract Half-Year, shall deliver to MSK true and accurate reports, giving such particulars of the business conducted by LICENSEE and its Sublicensees during the preceding six-month period under this Agreement. The reports shall include at least the following information, to be itemized per Licensed Product and/ or Licensed Service: (a) volumes, and unique identifiers (e.g., SKU or otherwise), of Licensed Products sold or otherwise distributed; (b) total revenue received on account of (i) Licensed Products sold or otherwise distributed, and (ii) other revenue bearing activities subject to payment hereunder; (c) Deductible Expenses (as provided in the definition of “Net Sales”); (d) Net Sales; (e) the portion of Net Sales that was received from Sublicensees; (f) total royalties due: (g) country of sale; (h) foreign currency conversion rate; and (i) any other consideration received in the prior quarter.
Appears in 3 contracts
Sources: License Agreement (Y-mAbs Therapeutics, Inc.), License Agreement (Y-mAbs Therapeutics, Inc.), License Agreement (Y-mAbs Therapeutics, Inc.)
Commercialization Reports. LICENSEE, within thirty (30) days of the end of each Contract Half-Year, shall deliver to MSK true and accurate reports, giving such particulars of the business conducted by LICENSEE and its Sublicensees during the preceding six-month period under this Agreement. The reports shall include at least the following information, to be itemized per Licensed Product and/ or Licensed Service:
(a) volumes, and unique identifiers (e.g., SKU or otherwise), of Licensed Products sold or otherwise distributed;
(b) total revenue received on account of (i) Licensed Products sold or otherwise distributed, and (ii) other revenue bearing activities subject to payment hereunder;
(c) Deductible Expenses (as provided in the definition of “Net Sales”);
(d) Net Sales;
(e) the portion of Net Sales that was received from Sublicensees;
(f) total royalties due:;
(g) country of sale;
(h) foreign currency conversion rate; and
(i) any other consideration received in the prior quarter.
Appears in 3 contracts
Sources: License Agreement (Y-mAbs Therapeutics, Inc.), License Agreement (Y-mAbs Therapeutics, Inc.), License Agreement (Y-mAbs Therapeutics, Inc.)
Commercialization Reports. LICENSEE, within thirty (30) days [****] of the end of each Contract Half-Year, shall deliver to MSK true and accurate reports, giving such particulars of the business conducted by LICENSEE and its Sublicensees during the preceding six-month period under this Agreement. The reports shall include at least the following information, to be itemized per Licensed Product and/ or Licensed Service:
(a) volumes, and unique identifiers (e.g., SKU or otherwise), of Licensed Products sold or otherwise distributed;
(b) total revenue received on account of (i) Licensed Products sold or otherwise distributed, and (ii) other revenue bearing activities subject to payment hereunder;
(c) Deductible Expenses (as provided in the definition of “Net Sales”);
(d) Net Sales;
(e) the portion of Net Sales that was received from Sublicensees;
(f) total royalties due:;
(g) country of sale;
(h) foreign currency conversion rate; and
(i) any other consideration received in the prior quarter.
Appears in 1 contract